Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos)

Arvind J. Trindade; Nikhil A. Kumta; Manoop S. Bhutani; Vinay Chandrasekhara; Pichamol Jirapinyo; Kumar Krishnan; Joshua Melson; Rahul Pannala; Mansour A. Parsi; Allison R. Schulman; Guru Trikudanathan; Rabindra R. Watson; John T. Maple; David R. Lichtenstein

doi:10.1016/j.gie.2020.03.018

Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos)

Arvind J. Trindade, Nikhil A. Kumta, Manoop S. Bhutani, Vinay Chandrasekhara, Pichamol Jirapinyo, Kumar Krishnan, Joshua Melson, Rahul Pannala, Mansour A. Parsi, Allison R. Schulman, Guru Trikudanathan, Rabindra R. Watson, John T. Maple, David R. Lichtenstein

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Background and Aims: Residual neoplasia after macroscopically complete EMR of large colon polyps has been reported in 10% to 32% of resections. Often, residual polyps at the site of prior polypectomy are fibrotic and nonlifting, making additional resection challenging. Methods: This document reviews devices and methods for the endoscopic treatment of fibrotic and/or residual polyps. In addition, techniques reported to reduce the incidence of residual neoplasia after endoscopic resection are discussed. Results: Descriptions of technologies and available outcomes data are summarized for argon plasma coagulation ablation, snare-tip coagulation, avulsion techniques, grasp-and-snare technique, EndoRotor endoscopic resection system, endoscopic full-thickness resection device, and salvage endoscopic submucosal dissection. Conclusions: Several technologies and techniques discussed in this document may aid in the prevention and/or resection of fibrotic and nonlifting polyps.

Original language	English (US)
Pages (from-to)	474-482
Number of pages	9
Journal	Gastrointestinal endoscopy
Volume	92
Issue number	3
DOIs	https://doi.org/10.1016/j.gie.2020.03.018
State	Published - Sep 2020

Bibliographical note

Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: N. Kumta: Consultant for Boston Scientific, Olympus Corporation of the Americas, Gyrus ACMI, Inc, and Apollo Endosurgery US Inc. A. Trindade: Consultant for Olympus Corporation of the Americas and PENTAX of America, Inc; food and beverage support from Boston Scientific; research grant from NinePoint Medical, Inc. M. Bhutani: Research grant from Silenseed Inc, Galera Inc, Oncosil Inc, and Augmenix Inc; food, beverage, or travel support from Boston Scientific, Augmentix, and Conmed Corporation. V. Chandrasekhara: Advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc. P. Jirapinyo: Consultant for GI Dynamics and Endogastric Solutions; research support from GI Dynamics, Apollo Endosurgery, and Fractyl. K. Krishnan: Consultant for Olympus Medical; D. Lichtenstein: Consultant for Allergan Inc, Augmenix, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; speaker for Aries Pharmaceutical, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; tuition payment from Erbe USA Inc. J. Melson: Investigator-initiated grant from Boston Scientific; stock options with Virgo Imaging. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; stockholder in AbbVie. A. Schulman: Consultant for Boston Scientific, Apollo Endosurgery, and MicroTech; research funding from GI Dynamics. G. Trikudanathan: Speaker, honorarium, and travel from Boston Scientific; advisory board for Abbvie. R. Watson: Consultant for Apollo Endosurgery, Boston Scientific, Medtronic, and Neptune Medical Inc; speaker for Apollo Endosurgery and Boston Scientific.

Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: N. Kumta: Consultant for Boston Scientific, Olympus Corporation of the Americas, Gyrus ACMI, Inc, and Apollo Endosurgery US Inc. A. Trindade: Consultant for Olympus Corporation of the Americas and PENTAX of America, Inc; food and beverage support from Boston Scientific; research grant from NinePoint Medical, Inc. M. Bhutani: Research grant from Silenseed Inc, Galera Inc, Oncosil Inc, and Augmenix Inc; food, beverage, or travel support from Boston Scientific, Augmentix, and Conmed Corporation. V. Chandrasekhara: Advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc. P. Jirapinyo: Consultant for GI Dynamics and Endogastric Solutions; research support from GI Dynamics, Apollo Endosurgery, and Fractyl. K. Krishnan: Consultant for Olympus Medical; D. Lichtenstein: Consultant for Allergan Inc, Augmenix, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; speaker for Aries Pharmaceutical, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; tuition payment from Erbe USA Inc. J. Melson: Investigator-initiated grant from Boston Scientific; stock options with Virgo Imaging. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; stockholder in AbbVie. A. Schulman: Consultant for Boston Scientific, Apollo Endosurgery, and MicroTech; research funding from GI Dynamics. G. Trikudanathan: Speaker, honorarium, and travel from Boston Scientific; advisory board for Abbvie. R. Watson: Consultant for Apollo Endosurgery, Boston Scientific, Medtronic, and Neptune Medical Inc; speaker for Apollo Endosurgery and Boston Scientific.

Publisher Copyright:
© 2020 American Society for Gastrointestinal Endoscopy

Access

10.1016/j.gie.2020.03.018

OpenUrl availability

Full text

Cite this

Trindade, A. J., Kumta, N. A., Bhutani, M. S., Chandrasekhara, V., Jirapinyo, P., Krishnan, K., Melson, J., Pannala, R., Parsi, M. A., Schulman, A. R., Trikudanathan, G., Watson, R. R., Maple, J. T., & Lichtenstein, D. R. (2020). Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos). Gastrointestinal endoscopy, 92(3), 474-482. https://doi.org/10.1016/j.gie.2020.03.018

Trindade, AJ, Kumta, NA, Bhutani, MS, Chandrasekhara, V, Jirapinyo, P, Krishnan, K, Melson, J, Pannala, R, Parsi, MA, Schulman, AR, Trikudanathan, G, Watson, RR, Maple, JT & Lichtenstein, DR 2020, 'Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos)', Gastrointestinal endoscopy, vol. 92, no. 3, pp. 474-482. https://doi.org/10.1016/j.gie.2020.03.018

@article{fbec907c8a994255a20c263125bfcd65,

title = "Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos)",

abstract = "Background and Aims: Residual neoplasia after macroscopically complete EMR of large colon polyps has been reported in 10% to 32% of resections. Often, residual polyps at the site of prior polypectomy are fibrotic and nonlifting, making additional resection challenging. Methods: This document reviews devices and methods for the endoscopic treatment of fibrotic and/or residual polyps. In addition, techniques reported to reduce the incidence of residual neoplasia after endoscopic resection are discussed. Results: Descriptions of technologies and available outcomes data are summarized for argon plasma coagulation ablation, snare-tip coagulation, avulsion techniques, grasp-and-snare technique, EndoRotor endoscopic resection system, endoscopic full-thickness resection device, and salvage endoscopic submucosal dissection. Conclusions: Several technologies and techniques discussed in this document may aid in the prevention and/or resection of fibrotic and nonlifting polyps.",

author = "Trindade, {Arvind J.} and Kumta, {Nikhil A.} and Bhutani, {Manoop S.} and Vinay Chandrasekhara and Pichamol Jirapinyo and Kumar Krishnan and Joshua Melson and Rahul Pannala and Parsi, {Mansour A.} and Schulman, {Allison R.} and Guru Trikudanathan and Watson, {Rabindra R.} and Maple, {John T.} and Lichtenstein, {David R.}",

note = "Funding Information: DISCLOSURE: The following authors disclosed financial relationships: N. Kumta: Consultant for Boston Scientific, Olympus Corporation of the Americas, Gyrus ACMI, Inc, and Apollo Endosurgery US Inc. A. Trindade: Consultant for Olympus Corporation of the Americas and PENTAX of America, Inc; food and beverage support from Boston Scientific; research grant from NinePoint Medical, Inc. M. Bhutani: Research grant from Silenseed Inc, Galera Inc, Oncosil Inc, and Augmenix Inc; food, beverage, or travel support from Boston Scientific, Augmentix, and Conmed Corporation. V. Chandrasekhara: Advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc. P. Jirapinyo: Consultant for GI Dynamics and Endogastric Solutions; research support from GI Dynamics, Apollo Endosurgery, and Fractyl. K. Krishnan: Consultant for Olympus Medical; D. Lichtenstein: Consultant for Allergan Inc, Augmenix, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; speaker for Aries Pharmaceutical, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; tuition payment from Erbe USA Inc. J. Melson: Investigator-initiated grant from Boston Scientific; stock options with Virgo Imaging. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; stockholder in AbbVie. A. Schulman: Consultant for Boston Scientific, Apollo Endosurgery, and MicroTech; research funding from GI Dynamics. G. Trikudanathan: Speaker, honorarium, and travel from Boston Scientific; advisory board for Abbvie. R. Watson: Consultant for Apollo Endosurgery, Boston Scientific, Medtronic, and Neptune Medical Inc; speaker for Apollo Endosurgery and Boston Scientific. Funding Information: DISCLOSURE: The following authors disclosed financial relationships: N. Kumta: Consultant for Boston Scientific, Olympus Corporation of the Americas, Gyrus ACMI, Inc, and Apollo Endosurgery US Inc. A. Trindade: Consultant for Olympus Corporation of the Americas and PENTAX of America, Inc; food and beverage support from Boston Scientific; research grant from NinePoint Medical, Inc. M. Bhutani: Research grant from Silenseed Inc, Galera Inc, Oncosil Inc, and Augmenix Inc; food, beverage, or travel support from Boston Scientific, Augmentix, and Conmed Corporation. V. Chandrasekhara: Advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc. P. Jirapinyo: Consultant for GI Dynamics and Endogastric Solutions; research support from GI Dynamics, Apollo Endosurgery, and Fractyl. K. Krishnan: Consultant for Olympus Medical; D. Lichtenstein: Consultant for Allergan Inc, Augmenix, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; speaker for Aries Pharmaceutical, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; tuition payment from Erbe USA Inc. J. Melson: Investigator-initiated grant from Boston Scientific; stock options with Virgo Imaging. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; stockholder in AbbVie. A. Schulman: Consultant for Boston Scientific, Apollo Endosurgery, and MicroTech; research funding from GI Dynamics. G. Trikudanathan: Speaker, honorarium, and travel from Boston Scientific; advisory board for Abbvie. R. Watson: Consultant for Apollo Endosurgery, Boston Scientific, Medtronic, and Neptune Medical Inc; speaker for Apollo Endosurgery and Boston Scientific. Publisher Copyright: {\textcopyright} 2020 American Society for Gastrointestinal Endoscopy",

year = "2020",

month = sep,

doi = "10.1016/j.gie.2020.03.018",

language = "English (US)",

volume = "92",

pages = "474--482",

journal = "Gastrointestinal endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos)

AU - Trindade, Arvind J.

AU - Kumta, Nikhil A.

AU - Bhutani, Manoop S.

AU - Chandrasekhara, Vinay

AU - Jirapinyo, Pichamol

AU - Krishnan, Kumar

AU - Melson, Joshua

AU - Pannala, Rahul

AU - Parsi, Mansour A.

AU - Schulman, Allison R.

AU - Trikudanathan, Guru

AU - Watson, Rabindra R.

AU - Maple, John T.

AU - Lichtenstein, David R.

N1 - Funding Information: DISCLOSURE: The following authors disclosed financial relationships: N. Kumta: Consultant for Boston Scientific, Olympus Corporation of the Americas, Gyrus ACMI, Inc, and Apollo Endosurgery US Inc. A. Trindade: Consultant for Olympus Corporation of the Americas and PENTAX of America, Inc; food and beverage support from Boston Scientific; research grant from NinePoint Medical, Inc. M. Bhutani: Research grant from Silenseed Inc, Galera Inc, Oncosil Inc, and Augmenix Inc; food, beverage, or travel support from Boston Scientific, Augmentix, and Conmed Corporation. V. Chandrasekhara: Advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc. P. Jirapinyo: Consultant for GI Dynamics and Endogastric Solutions; research support from GI Dynamics, Apollo Endosurgery, and Fractyl. K. Krishnan: Consultant for Olympus Medical; D. Lichtenstein: Consultant for Allergan Inc, Augmenix, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; speaker for Aries Pharmaceutical, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; tuition payment from Erbe USA Inc. J. Melson: Investigator-initiated grant from Boston Scientific; stock options with Virgo Imaging. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; stockholder in AbbVie. A. Schulman: Consultant for Boston Scientific, Apollo Endosurgery, and MicroTech; research funding from GI Dynamics. G. Trikudanathan: Speaker, honorarium, and travel from Boston Scientific; advisory board for Abbvie. R. Watson: Consultant for Apollo Endosurgery, Boston Scientific, Medtronic, and Neptune Medical Inc; speaker for Apollo Endosurgery and Boston Scientific. Funding Information: DISCLOSURE: The following authors disclosed financial relationships: N. Kumta: Consultant for Boston Scientific, Olympus Corporation of the Americas, Gyrus ACMI, Inc, and Apollo Endosurgery US Inc. A. Trindade: Consultant for Olympus Corporation of the Americas and PENTAX of America, Inc; food and beverage support from Boston Scientific; research grant from NinePoint Medical, Inc. M. Bhutani: Research grant from Silenseed Inc, Galera Inc, Oncosil Inc, and Augmenix Inc; food, beverage, or travel support from Boston Scientific, Augmentix, and Conmed Corporation. V. Chandrasekhara: Advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc. P. Jirapinyo: Consultant for GI Dynamics and Endogastric Solutions; research support from GI Dynamics, Apollo Endosurgery, and Fractyl. K. Krishnan: Consultant for Olympus Medical; D. Lichtenstein: Consultant for Allergan Inc, Augmenix, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; speaker for Aries Pharmaceutical, Gyrus ACMI, Inc, and Olympus Corporation of the Americas; tuition payment from Erbe USA Inc. J. Melson: Investigator-initiated grant from Boston Scientific; stock options with Virgo Imaging. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; stockholder in AbbVie. A. Schulman: Consultant for Boston Scientific, Apollo Endosurgery, and MicroTech; research funding from GI Dynamics. G. Trikudanathan: Speaker, honorarium, and travel from Boston Scientific; advisory board for Abbvie. R. Watson: Consultant for Apollo Endosurgery, Boston Scientific, Medtronic, and Neptune Medical Inc; speaker for Apollo Endosurgery and Boston Scientific. Publisher Copyright: © 2020 American Society for Gastrointestinal Endoscopy

PY - 2020/9

Y1 - 2020/9

N2 - Background and Aims: Residual neoplasia after macroscopically complete EMR of large colon polyps has been reported in 10% to 32% of resections. Often, residual polyps at the site of prior polypectomy are fibrotic and nonlifting, making additional resection challenging. Methods: This document reviews devices and methods for the endoscopic treatment of fibrotic and/or residual polyps. In addition, techniques reported to reduce the incidence of residual neoplasia after endoscopic resection are discussed. Results: Descriptions of technologies and available outcomes data are summarized for argon plasma coagulation ablation, snare-tip coagulation, avulsion techniques, grasp-and-snare technique, EndoRotor endoscopic resection system, endoscopic full-thickness resection device, and salvage endoscopic submucosal dissection. Conclusions: Several technologies and techniques discussed in this document may aid in the prevention and/or resection of fibrotic and nonlifting polyps.

AB - Background and Aims: Residual neoplasia after macroscopically complete EMR of large colon polyps has been reported in 10% to 32% of resections. Often, residual polyps at the site of prior polypectomy are fibrotic and nonlifting, making additional resection challenging. Methods: This document reviews devices and methods for the endoscopic treatment of fibrotic and/or residual polyps. In addition, techniques reported to reduce the incidence of residual neoplasia after endoscopic resection are discussed. Results: Descriptions of technologies and available outcomes data are summarized for argon plasma coagulation ablation, snare-tip coagulation, avulsion techniques, grasp-and-snare technique, EndoRotor endoscopic resection system, endoscopic full-thickness resection device, and salvage endoscopic submucosal dissection. Conclusions: Several technologies and techniques discussed in this document may aid in the prevention and/or resection of fibrotic and nonlifting polyps.

UR - http://www.scopus.com/inward/record.url?scp=85087515503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087515503&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2020.03.018

DO - 10.1016/j.gie.2020.03.018

M3 - Article

C2 - 32641215

AN - SCOPUS:85087515503

SN - 0016-5107

VL - 92

SP - 474

EP - 482

JO - Gastrointestinal endoscopy

JF - Gastrointestinal endoscopy

IS - 3

ER -

Devices and techniques for endoscopic treatment of residual and fibrotic colorectal polyps (with videos)

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this